Subscribe To
EXEL / Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology
EXEL News
By Zacks Investment Research
November 2, 2023
Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated
Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance. more_horizontal
By Zacks Investment Research
November 1, 2023
Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended September 2023, it could be more_horizontal
By Zacks Investment Research
October 27, 2023
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the sto more_horizontal
By Zacks Investment Research
October 12, 2023
EXEL vs. TECH: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But more_horizontal
By InvestorPlace
September 20, 2023
3 Biotech Stocks That Should Be on Every Investor's Radar This Fall
The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rate more_horizontal
By Zacks Investment Research
September 13, 2023
Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor. more_horizontal
By Market Watch
September 12, 2023
Exelixis to license Insilico AI-designed cancer drug
Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insil more_horizontal
By Zacks Investment Research
September 5, 2023
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Illumina (ILMN). But whi more_horizontal